A recent study indicated that glypican-3 (GPC-3), an oncofetal proteoglycan anchored to the HCC cell membrane and associated with HCC progression, would provide a novel immunotherapeutic target in the treatment of HCC [178]. This evidence concerns the gene GPC3 and hepatocellular carcinoma.